The DoD and VA-led initiative is moving beyond its initial focus on lung cancer to add analyses of multiple cancer types and a prospective, multisite study.
The ability to effectively use FFPE tissue opens up a large number of clinical samples for analysis, many with quality data on patient demographics, treatment, and outcomes.
The researchers used a combination of genomic, transcriptomic, and proteomic analyses to study mechanisms of resistance to the pan-PI3K inhibitor buparlisib.
Called LinkedOmics, the resource features three modules for analyzing multi-omic data collected in projects encompassing 11,158 patients and 32 cancer types.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
Researcher Amanda Paulovich will develop multiple-reaction monitoring mass spectrometry assays and apply them to samples from cancer patients in the program.
According to NCI, the MOUs will facilitate the coordination of research and sharing of data and tests for use by scientists and oncologists around the world.
Under the collaboration, University of Victoria researchers will add 2,000 new multiple reaction-monitoring mass spec assays to the CPTAC Assay Portal.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.
